PRINCETON, N.J. --(BUSINESS WIRE)--Jul. 7, 2021-- UroGen Pharma Ltd (Nasdaq:URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that it will present at the Ladenburg Thalmann Healthcare
PRINCETON, N.J. --(BUSINESS WIRE)--Jun. 4, 2021-- UroGen Pharma Ltd. (Nasdaq: URGN) a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced the grants of inducement restricted stock units (“RSUs”) to
PRINCETON, N.J. --(BUSINESS WIRE)--May 25, 2021-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that it will present at the following virtual conferences in
Jelmyto ® net product revenue of $7.5 million for the first quarter of 2021 New patient starts in March and April of 2021 increased 100% and 165%, respectively, compared to new patient starts in January 2021 Phase 3 ATLAS trial enrollment ongoing with new sites activated in Europe Active platform
Conference Call and Webcast Scheduled for Thursday, May 13, 2021 at 8:30 AM ET PRINCETON, N.J. --(BUSINESS WIRE)--May 6, 2021-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic
Achieved Jelmyto ® net product revenue of $8.0 million for the fourth quarter of 2020; $11.8 million in first seven months of commercialization Initiated ATLAS Phase III trial for UGN-102 and actively enrolling patients with low-grade intermediate risk NMIBC Expanded immuno-oncology pipeline with
RTW Investments, LP will provide UroGen with an upfront cash payment of $75 million and will receive tiered future payments based on worldwide annual net product sales of Jelmyto ® and UGN-102, if approved Strategic funding partnership with RTW Investments, LP enables UroGen to further support the
Exploratory research at the Johns Hopkins University to study checkpoint inhibitors combined with RTGel ™ in Glioblastoma Multiforme PRINCETON, N.J. --(BUSINESS WIRE)--Mar. 15, 2021-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel
Conference Call and Webcast Scheduled for Thursday, March 18, 2021 at 8:30 AM ET PRINCETON, N.J. --(BUSINESS WIRE)--Mar. 11, 2021-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic
PRINCETON, N.J. --(BUSINESS WIRE)--Mar. 5, 2021-- UroGen Pharma Ltd. (Nasdaq: URGN) a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced the grants of inducement restricted stock units (“RSUs”) to